Cancer Drug Resistance

Part I. Physiological Resistance

The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors

Mark W. Dewhirst, Yiting Cao, Benjamin Moeller, and Chuan-Yuan Li

Influence of Tumor pH on Therapeutic Response

Chang W. Song, Robert Griffin, and Heon Joo Park

Tumor Oxygenation and Treatment Response

Sarah Jane Lunt and Richard P. Hill

Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance: The Role of Evolving Interrelationships Between Cancer Cells and Host Tissues

Janusz W. Rak, Brenda Coomber, and Joanne L. Yu

PET Imaging of Response and Resistance to Cancer Therapy

David A. Mankoff and Kenneth A. Krohn

Part II: Biological Resistance

Cancer Stem Cells: Implications for Development of More Effective Therapies

Ilia Mantle, Gabriela Dontu, Suling Liu, and Max S. Wicha

Therapeutic Resistance in Leukemia

William R. Waud

Tumor Site Implantation and Animal Model Selection in Oncology

Anibal A. Arjona and Enrique Alvarez

In Vivo Resistance

Beverly A. Teicher

Characteristics of the Metastatic Phenotype: The Melanoma Experience

Vladislava O. Melnikova and Menashe Bar-Eli

The Microenvironment and Drug Resistance

Patrice J. Morin

Part III. Biochemical Resistance

Glutathione and Glutathione S-Transferases in Drug Resistance

Victoria J. Findlay, Danyelle M. Townsend, and Kenneth D. Tew

Metallothioneins in Drug Resistance

Faiyaz Notta and D. James Koropatnick

Molecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors

Elena Monti

New and Revised Concepts in Multidrug Resistance: Sestamibi, SNPs, Substrates, and Stem Cells

Susan E. Bates, John Deeken, Chaohong Fan, and Robert W. Robey

Cisplatin Resistance: Molecular Basis of a Multifaceted Impediment

Zahid H. Siddik

Regulation of the Cellular Pharmacology and Cytotoxicity of Cisplatin by Copper Transporters

Roohangiz Safaei and Stephen B. Howell

Resistance to Taxanes

Lee M. Greenberger

Cancer Drug Resistance represents a point on the path of the long journey toward understanding the complex interactions between host, tumor and cytotoxic or immunomodulatory agents. It addresses the resistance of solid tumors to anticancer therapeutics by considering mechanisms that involve alterations in genetics and epigenetics, cellular biochemistry, properties related to physiology of the solid tumor mass and alterations in host metabolic and immune status induced by the presence of malignant disease.